Ignite Creation Date:
2025-12-24 @ 6:57 PM
Ignite Modification Date:
2026-01-22 @ 6:31 AM
Study NCT ID:
NCT00946257
Status:
COMPLETED
Last Update Posted:
2017-06-01
First Post:
2009-07-23
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Subcutaneous Administration of Otelixizumab to T1DM Patients
Sponsor:
GlaxoSmithKline
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
112438
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None